Samuel S Lee

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi request reprint Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice
    S S Lee
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 23:397-408. 2006
  2. doi request reprint Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
    Samuel S Lee
    University of Calgary, Calgary, AB, Canada
    Liver Int 32:1270-7. 2012
  3. pmc Cirrhotic cardiomyopathy
    Soon Koo Baik
    Dept of Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea
    Orphanet J Rare Dis 2:15. 2007
  4. ncbi request reprint Histological response to interferon alfa-based therapies in hepatitis C
    Samuel S Lee
    Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Semin Liver Dis 24:55-60. 2004
  5. ncbi request reprint Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C
    S S Lee
    Liver Unit, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Aliment Pharmacol Ther 17:611-21. 2003
  6. ncbi request reprint Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?
    Samuel S Lee
    Liver Unit, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1
    J Antimicrob Chemother 51:487-91. 2003
  7. pmc Cardiovascular determinants of survival in cirrhosis
    Samuel S Lee
    Liver Unit, University of Calgary, Calgary, Canada
    Gut 56:746-8. 2007
  8. doi request reprint Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
    S S Lee
    University of Calgary Liver Unit, Calgary, Alberta, Canada
    Aliment Pharmacol Ther 35:37-47. 2012
  9. ncbi request reprint Cirrhotic cardiomyopathy
    Hongqun Liu
    Liver Unit, GI Research Group, University of Calgary, Calgary, Canada
    Gastroenterol Clin Biol 26:842-7. 2002
  10. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002

Collaborators

Detail Information

Publications68

  1. ncbi request reprint Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice
    S S Lee
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Aliment Pharmacol Ther 23:397-408. 2006
    ..Pegylated interferon alfa-2a (40 KD) plus ribavirin therapy induces sustained virological response rates up to 63% in randomized-controlled trials...
  2. doi request reprint Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
    Samuel S Lee
    University of Calgary, Calgary, AB, Canada
    Liver Int 32:1270-7. 2012
    ..This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin...
  3. pmc Cirrhotic cardiomyopathy
    Soon Koo Baik
    Dept of Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea
    Orphanet J Rare Dis 2:15. 2007
    ..The extent of cirrhotic cardiomyopathy generally correlates to the degree of liver insufficiency. Reversibility is possible (either pharmacological or after liver transplantation), but further studies are needed...
  4. ncbi request reprint Histological response to interferon alfa-based therapies in hepatitis C
    Samuel S Lee
    Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Semin Liver Dis 24:55-60. 2004
    ..In the future, the development of serum markers of fibrosis may allow for monitoring of hepatic fibrosis and histological response to therapy without the need to perform repeat liver biopsy...
  5. ncbi request reprint Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C
    S S Lee
    Liver Unit, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Aliment Pharmacol Ther 17:611-21. 2003
    ..Therefore, a decision to stop or continue treatment can be based on a positive viral RNA test at 12 weeks for interferon-naive patients receiving interferon or pegylated interferon therapy...
  6. ncbi request reprint Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?
    Samuel S Lee
    Liver Unit, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1
    J Antimicrob Chemother 51:487-91. 2003
  7. pmc Cardiovascular determinants of survival in cirrhosis
    Samuel S Lee
    Liver Unit, University of Calgary, Calgary, Canada
    Gut 56:746-8. 2007
  8. doi request reprint Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
    S S Lee
    University of Calgary Liver Unit, Calgary, Alberta, Canada
    Aliment Pharmacol Ther 35:37-47. 2012
    ..The efficacy of individualised antiviral treatment durations for chronic hepatitis C remains unclear...
  9. ncbi request reprint Cirrhotic cardiomyopathy
    Hongqun Liu
    Liver Unit, GI Research Group, University of Calgary, Calgary, Canada
    Gastroenterol Clin Biol 26:842-7. 2002
  10. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  11. ncbi request reprint Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values
    S S Lee
    Liver Unit, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta T2N 4N1, Canada
    J Viral Hepat 8:202-5. 2001
    ..Controlled trials of this treatment in this subgroup of patients with hepatitis C are warranted...
  12. ncbi request reprint AASLD 2005 distinguished achievement award to Dr. Jenny Heathcote
    Samuel S Lee
    Liver Unit, University of Calgary, Canada
    Hepatology 42:1244-5. 2005
  13. ncbi request reprint Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4
    Samuel S Lee
    Liver Unit, University of Calgary, Calgary, Alberta, Canada
    Antivir Ther 13:9-16. 2008
    ..Here, we discuss the importance of baseline predictors of response and the emerging concept of response-guided therapy in genotype 1 and 4 patients...
  14. pmc Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids
    Ying Ying Yang
    Liver Unit, Faculty of Medicine, University of Calgary, Calgary, Canada
    J Hepatol 53:298-306. 2010
    ..We therefore aimed to clarify the relationship between the TNFalpha-NFkappaB pathway and endocannabinoids in the pathogenesis of cardiodepression of cholestatic bile duct ligated (BDL) mice...
  15. doi request reprint How to optimize HCV therapy in genotype 1 patients: management of side-effects
    Angeli Chopra
    University of Calgary Liver Unit, Calgary, Canada
    Liver Int 33:30-4. 2013
    ..Successful adherence to treatment can be enhanced by a strong support network for the patient, including specially-trained hepatitis nurses and a multidisciplinary team incorporating pharmacists, counsellors and social workers...
  16. pmc Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
    Kelly W Burak
    Liver Unit, Division of Gastroenterologyand Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Can J Gastroenterol 27:273-80. 2013
    ..Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and has demonstrated efficacy in other autoimmune conditions...
  17. doi request reprint Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats
    Li Liu
    Liver Unit, University of Calgary, Calgary, AB T2N 4N1, Canada
    Dig Liver Dis 44:1012-7. 2012
    ..Erythropoietin exerts cardioprotective effects. The present study aimed to investigate the therapeutic effects of erythropoietin on cirrhotic cardiomyopathy...
  18. pmc Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
    J Powis
    Department of Medicine, University of Toronto, Toronto, ON, Canada
    J Viral Hepat 15:52-7. 2008
    ..027). There is significant interaction between cirrhosis and genotype 3 leading to a poor antiviral response in such patients requiring an alternate management strategy. This finding should be confirmed in a larger population...
  19. doi request reprint Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial
    Robert J Hilsden
    Department of Medicine, University of Calgary, Calgary, AB, Canada
    Clin Infect Dis 57:S90-6. 2013
    ..This study investigated the efficacy and safety of directly observed pegylated interferon (peg-IFN) alfa-2a plus self-administered ribavirin (RBV) for the treatment of hepatitis C virus (HCV) among people with active drug use...
  20. pmc Cardiac and vascular changes in cirrhosis: pathogenic mechanisms
    Hongqun Liu
    Liver Unit, Department of Medicine, University of Calgary 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada
    World J Gastroenterol 12:837-42. 2006
    ..Future work should address the complex interrelationships between these systems...
  21. doi request reprint Prediction of cardiac complications after liver transplantation
    Tamer R Fouad
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Transplantation 87:763-70. 2009
    ..Orthotopic liver transplantation (OLT) stresses the cardiovascular system, and cardiac complications after OLT are common...
  22. doi request reprint B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid
    Robert P Myers
    Liver Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Am J Gastroenterol 108:933-41. 2013
    ..The objective of this study was to assess the safety and efficacy of rituximab in patients with PBC refractory to UDCA...
  23. ncbi request reprint Cirrhotic cardiomyopathy
    Waleed Al Hamoudi
    Liver Unit, University of Calgary, Calgary, Alberta, Canada
    Ann Hepatol 5:132-9. 2006
    ..The prolonged QT interval normalizes following liver transplantation. Thus, liver transplantation appears to be the ultimate treatment for the cardiovascular complications of cirrhosis...
  24. ncbi request reprint Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus
    Carla S Coffin
    Liver Unit, Division of Gastroenterology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Liver Int 27:722-6. 2007
    ..Hepatitis B virus (HBV) and hepatitis C virus (HCV) share similar transmission routes; thus, coinfection is frequent. The consequences of acute HBV infection in patients with chronic hepatitis C are unknown...
  25. ncbi request reprint Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus
    Nazira Chatur
    Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Liver Int 25:723-7. 2005
    ..Novel drug treatments include immunosuppressive drugs such as tacrolimus (TAC), mycophenolate mofetil (MMF), methotrexate and cyclosporine. We describe a multi-centre Canadian experience with MMF and TAC...
  26. doi request reprint Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide
    Yang Li
    Liver Unit, Gastrointestinal Research Group, Calgary, Alberta, Canada
    Am J Physiol Gastrointest Liver Physiol 295:G252-9. 2008
    ..The first two abnormalities were caused by neuronal NOS-derived nitric oxide...
  27. ncbi request reprint Management of hepatitis C virus genotype 4
    Ayman A Abdo
    Liver Unit, University of Calgary, Calgary, Alberta, Canada
    J Gastroenterol Hepatol 19:1233-9. 2004
    ..Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed...
  28. doi request reprint Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin
    V G Bain
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Aliment Pharmacol Ther 28:43-50. 2008
    ..The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice...
  29. ncbi request reprint The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver
    Yang Li
    Gastrointestinal Research Group, Department of Medicine, University of Calgary, Calgary, Canada
    Eur J Immunol 32:3443-52. 2002
    ..In conclusion, adenovirus vectors induce rapid neutrophil-mediated inflammation in the post-sinusoidal venules by selectins and alpha(4)-integrin but surprisingly not by CD18...
  30. doi request reprint Acute-on-chronic liver failure: the heart and systemic hemodynamics
    Hongqun Liu
    Liver Unit, University of Calgary, Calgary, Canada
    Curr Opin Crit Care 17:190-4. 2011
    ..The extent of circulatory abnormalities is further exaggerated in acute-on-chronic liver failure (ACLF). The mechanism remains unclear and management also needs to be evaluated...
  31. doi request reprint Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats
    Tamara K Glenn
    Liver Unit, GI Research Group, Calgary, Canada
    J Hepatol 55:1249-55. 2011
    ..The present study investigated the role of passive tension regulators - titin and collagen - in the pathogenesis of this condition...
  32. ncbi request reprint Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis
    Gilaad G Kaplan
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 13:1401-7. 2007
    ..The aims of the present study were (1) to determine the incidence of dysplasia or CRC, (2) to assess surveillance practices, and (3) to assess the costs associated with surveillance of PSC patients...
  33. ncbi request reprint Cardiac dysfunction in cirrhosis
    Ralph F Lee
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Best Pract Res Clin Gastroenterol 21:125-40. 2007
    ..In this review, the clinical features, pathogenic mechanisms, clinical consequences and management options for cirrhotic cardiomyopathy are discussed...
  34. doi request reprint Treatment of HBeAg-positive patients with nucleos/tide analogues
    Carla S Coffin
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Liver Int 29:116-24. 2009
    ..This review includes the range of treatment options and criteria for determining when and how to most effectively intervene with antiviral therapy for chronically infected patients positive for the HBeAg...
  35. ncbi request reprint Therapy insight: Cirrhotic cardiomyopathy
    Seyed A Gaskari
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Nat Clin Pract Gastroenterol Hepatol 3:329-37. 2006
    ..The clinical features, general diagnostic criteria, pathogenesis and treatment of cirrhotic cardiomyopathy are discussed in this review...
  36. doi request reprint Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis
    Matthew D Sadler
    University of Calgary Liver Unit, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada
    Expert Opin Pharmacother 14:1363-9. 2013
    ..Several studies have now shown nucleot(s)ide analogs to be safe and effective in decompensated cirrhosis due to CHB...
  37. doi request reprint Portal vein thrombosis: should anticoagulation be used?
    Stephen E Congly
    Department of Medicine, University of Calgary Liver Unit, 3330 Hospital Drive NW, Calgary, AB, Canada, T2N 4N1
    Curr Gastroenterol Rep 15:306. 2013
    ..Newer evidence suggests that prophylactic anticoagulation in patients with cirrhosis may have a role in clinical management with decreased incidence of PVT and improved survival; further study is needed...
  38. pmc Emergency management of bleeding esophageal varices: drugs, bands or sleep?
    Brian M Yan
    Division of Gastroenterology, University of Calgary, Alberta
    Can J Gastroenterol 20:165-70. 2006
    ..Although the literature cannot yet definitively answer the question posed, the authors suggest that delaying endoscopic treatment until the next morning may be the most reasonable practical approach...
  39. doi request reprint Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy
    Hongqun Liu
    Liver Unit, University of Calgary, Calgary, AB, Canada
    Liver Int 28:640-8. 2008
    ..Nuclear factor-kappaB (NF-kappaB) is crucial for cytokine regulation, and induces cardiac dysfunction in several heart disease models. We aimed to elucidate possible NF-kappaB involvement in cirrhotic cardiomyopathy...
  40. pmc Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers
    Robert P Myers
    University of Calgary, Calgary, Canada
    Can J Gastroenterol 21:169-75. 2007
    ....
  41. ncbi request reprint The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis
    Gilaad G Kaplan
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Am J Gastroenterol 102:1042-9. 2007
    ....
  42. ncbi request reprint Role of ICAM-1 in chronic hepatic allograft rejection in the rat
    John Wong
    Liver Unit, Gastroenterology Research Group, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    Am J Physiol Gastrointest Liver Physiol 283:G196-203. 2002
    ..These results showed that early leukocyte recruitment in the hepatic microvasculature of rejecting allografts is ICAM-1 dependent and suggest that impacting on early cell recruitment can significantly ameliorate chronic rejection...
  43. ncbi request reprint Acute coinfection with hepatitis B and hepatitis C viruses
    Brian M Yan
    Liver Unit, University of Calgary, Calgary, Alberta
    Can J Gastroenterol 19:729-30. 2005
    ..The few previously reported cases all describe acute HBV followed by acute HCV, leading to HBV clearance but chronic HCV. This is the first reported case of acute concurrent infection and spontaneous clearance of both HBV and HCV...
  44. ncbi request reprint Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice
    Soon Woo Nam
    Liver Unit, University of Calgary, Calgary, Canada
    Clin Sci (Lond) 127:519-26. 2014
    ..These results suggest that apoptosis contributes to depressed cardiac contractility in a murine model of cirrhotic cardiomyopathy. ..
  45. ncbi request reprint Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression
    Daisheng Song
    Liver Unit, Gastroenterology Research Group, and Neuroscience Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Hepatology 35:159-66. 2002
    ..We conclude that the activation of central cardiovascular-regulatory nuclei, through a c-fos-dependent pathway, is necessary for development of hyperdynamic circulation in portal-hypertensive rats...
  46. doi request reprint Hepatic nodular regenerative hyperplasia in a patient with advanced carcinoid tumor
    Waleed K Al-Hamoudi
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Eur J Gastroenterol Hepatol 21:1083-5. 2009
    ..This association has not been reported earlier...
  47. ncbi request reprint Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome
    Ayman A Abdo
    Liver Unit, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
    Hepatology 36:1393-9. 2002
    ..In conclusion, patients with well-established AIH can, after variable duration of follow-up, develop PSC. In patients with AIH who become resistant to immunosuppression or develop significant cholestasis, PSC should be ruled out by ERCP...
  48. pmc Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats
    Seyed Ali Gaskari
    Liver Unit, Faculty of Medicine, University of Calgary, Alberta, Canada
    Br J Pharmacol 146:315-23. 2005
    ..The increased tachycardia-stress-induced release of endocannabinoids may help explain why contractility is normal at baseline but attenuated with stress...
  49. ncbi request reprint Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C
    R P Myers
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    J Viral Hepat 8:249-55. 2001
    ..Alternate noninvasive methods of predicting hepatic fibrosis are needed...
  50. doi request reprint Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies
    Kally Cheung
    Alberta Health Services, Calgary, Alberta, Canada
    Clin Gastroenterol Hepatol 10:117-25. 2012
    ..Studies have indicated that branched chain aromatic acid can be given as therapeutic nutrients, and that probiotics and nocturnal feeding improve patient outcomes...
  51. pmc Chronic hepatitis B--who should be treated?
    Carla S Coffin
    Liver Unit, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
    MedGenMed 8:75. 2006
    ..This review includes criteria for determining when and how to most effectively intervene with antiviral therapy for chronically infected patients...
  52. ncbi request reprint Amiodarone hepatotoxicity
    Mohamed Babatin
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Curr Vasc Pharmacol 6:228-36. 2008
    ....
  53. ncbi request reprint Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations
    Robert P Myers
    Liver Unit, University of Calgary, Alberta, Canada
    Hepatology 37:393-400. 2003
    ..Hepatic fibrosis is common, but does not correlate with systemic or hepatic hemodynamics...
  54. pmc Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats
    Y Li
    Liver Unit, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Gut 52:293-9. 2003
    ..Our previous study revealed that primary afferent denervation by neonatal capsaicin treatment prevented the development of hyperdynamic circulation in portal hypertensive and cirrhotic rats...
  55. ncbi request reprint Hemodynamic characterization of arterialized and nonarterialized liver transplants in the rat
    J Wong
    Gastroenterology Research Group, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    Can J Gastroenterol 15:435-40. 2001
    ....
  56. ncbi request reprint Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal
    R P Myers
    Division of Gastroenterology and Hepatology, University of Calgary, Alberta
    Can J Gastroenterol 14:725-7. 2000
    ..Until further data are available regarding the safety of withdrawal of these agents, indefinite treatment may be required in patients with established cirrhosis...
  57. pmc Hepatic venous dysregulation contributes to blood volume pooling in cirrhotic rats
    Y Li
    Liver Unit, GI Research Group, University of Calgary, AB, T2N 4N1, Canada
    Gut 55:1030-5. 2006
    ..As the gut/liver veins are the major blood reservoir, this suggests hepatosplanchnic venous pooling. We therefore aimed to elucidate the vasoactive responses of the hepatic veins in cirrhosis...
  58. ncbi request reprint Silymarin treatment of viral hepatitis: a systematic review
    K E Mayer
    Liver Unit, Department of Medicine, University of Calgary, Calgary, Canada
    J Viral Hepat 12:559-67. 2005
    ..Nevertheless it may be worthwhile to determine its effects in conjunction with standard antiviral treatment...
  59. ncbi request reprint A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
    Seng Gee Lim
    National University Hospital, Singapore
    Arch Intern Med 166:49-56. 2006
    ..Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B virus (HBV)...
  60. ncbi request reprint Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells
    Tram N Q Pham
    Molecular Virology and Hepatology Research, Division of Basic Medical Science, Faculty of Medicine, Health Sciences Centre, Memorial University, St John s, Newfoundland, Canada A1B 3V6
    J Gen Virol 86:657-66. 2005
    ..As such, this method offers a new investigative tool to study HCV lymphotropism and to monitor virus presence during the course of HCV infection...
  61. doi request reprint Cirrhotic cardiomyopathy
    Saleh A Alqahtani
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Semin Liver Dis 28:59-69. 2008
    ..Treatment of this condition is mainly supportive. Orthotopic liver transplantation appears to improve or normalize the condition, generally after a period of several months...
  62. ncbi request reprint Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study
    Moon Young Kim
    Department of Internal Medicine and Institute of Lifelong Health, Wonju College of Medicine, Yonsei University, Wonju, South Korea
    Liver Int 27:1103-10. 2007
    ..We prospectively evaluated the correlation between the extent of abnormal Doppler HV waveforms expressed as damping index (DI) and the hepatic venous pressure gradient (HVPG) and response to propranolol in patients with cirrhosis...
  63. ncbi request reprint Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy?
    Samuel S Lee
    Hepatology 38:1089-91. 2003
  64. ncbi request reprint Nitric oxide and renal and cardiac dysfunction in cirrhosis
    Joaquin Garcia-Estan
    Departamento de Fisiologia, Facultad de Medicina, Universidad de Murcia, Murcia 30100, Spain
    Clin Sci (Lond) 102:213-22. 2002
    ..Another gas that transduces its signal through cGMP, carbon monoxide, is also likely to play a role in cirrhotic cardiomyopathy, but the nature of the interaction between NO and carbon monoxide in this syndrome remains unclear...
  65. ncbi request reprint Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison
    Soon Koo Baik
    Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea
    Am J Gastroenterol 100:631-5. 2005
    ..They purportedly act by mesenteric arterial vasoconstriction, thus reducing portal venous flow (PVF) and portal pressure. Little is known about the immediate-early hemodynamic effects of these drugs...
  66. doi request reprint How to write a paper: an editor's tips
    Samuel S Lee
    Liver Int 28:421-2. 2008
  67. ncbi request reprint Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response
    Soon Koo Baik
    Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan dong, Wonju 220 701, South Korea
    Radiology 240:574-80. 2006
    ..To prospectively evaluate both the correlation between abnormal Doppler ultrasonography (US) hepatic vein waveforms and the hepatic venous pressure gradient (HVPG) and the response to drug treatment in patients with cirrhosis...
  68. pmc Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey
    Justin Cheung
    Department of Medicine, University of Alberta, Edmonton
    Can J Gastroenterol 20:531-4. 2006
    ..Guidelines have been published in 1997; however, variability in the acute management and prevention of EVB rebleeding may occur...